These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31720367)

  • 1. The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.
    Burns DK; Chiang C; Welsh-Bohmer KA; Brannan SK; Culp M; O'Neil J; Runyan G; Harrigan P; Plassman BL; Lutz M; Lai E; Haneline S; Yarnall D; Yarbrough D; Metz C; Ponduru S; Sundseth S; Saunders AM
    Alzheimers Dement (N Y); 2019; 5():661-670. PubMed ID: 31720367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
    Schneider LS; Bennett DA; Farlow MR; Peskind ER; Raskind MA; Sano M; Stern Y; Haneline S; Welsh-Bohmer KA; O'Neil J; Walter R; Maresca S; Culp M; Alexander R; Saunders AM; Burns DK; Chiang C
    J Prev Alzheimers Dis; 2022; 9(4):625-634. PubMed ID: 36281666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOMMORROW neuropsychological battery: German language validation and normative study.
    Romero HR; Monsch AU; Hayden KM; Plassman BL; Atkins AS; Keefe RSE; Brewster S; Chiang C; O'Neil J; Runyan G; Atkinson MJ; Crawford S; Budur K; Burns DK; Welsh-Bohmer KA
    Alzheimers Dement (N Y); 2018; 4():314-323. PubMed ID: 30094331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E for Alzheimer's disease and mild cognitive impairment.
    Isaac MG; Quinn R; Tabet N
    Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New applications of disease genetics and pharmacogenetics to drug development.
    Roses AD; Saunders AM; Lutz MW; Zhang N; Hariri AR; Asin KE; Crenshaw DG; Budur K; Burns DK; Brannan SK
    Curr Opin Pharmacol; 2014 Feb; 14():81-9. PubMed ID: 24565016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.
    Reiman EM; Langbaum JB; Fleisher AS; Caselli RJ; Chen K; Ayutyanont N; Quiroz YT; Kosik KS; Lopera F; Tariot PN
    J Alzheimers Dis; 2011; 26 Suppl 3(Suppl 3):321-9. PubMed ID: 21971471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MG; Tabet N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
    Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR
    J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of
    Nishimura A; Nonomura H; Tanaka S; Yoshida M; Maruyama Y; Aritomi Y; Saunders AM; Burns DK; Lutz MW; Runyan G; Lai E; Budur K; Roses AD
    Alzheimers Dement (N Y); 2017 Nov; 3(4):524-530. PubMed ID: 29124110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults.
    Knodt AR; Burke JR; Welsh-Bohmer KA; Plassman BL; Burns DK; Brannan SK; Kukulka M; Wu J; Hariri AR
    Alzheimers Dement (N Y); 2019; 5():254-263. PubMed ID: 31304231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
    Kondo T; Banno H; Okunomiya T; Amino Y; Endo K; Nakakura A; Uozumi R; Kinoshita A; Tada H; Morita S; Ishikawa H; Shindo A; Yasuda K; Taruno Y; Maki T; Suehiro T; Mori K; Ikeda M; Fujita K; Izumi Y; Kanemaru K; Ishii K; Shigenobu K; Kutoku Y; Sunada Y; Kawakatsu S; Shiota S; Watanabe T; Uchikawa O; Takahashi R; Tomimoto H; Inoue H
    BMJ Open; 2021 Jun; 11(6):e051343. PubMed ID: 34193504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
    Miller BW; Willett KC; Desilets AR
    Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Kehoe PG; Turner N; Howden B; Jarutyte L; Clegg SL; Malone IB; Barnes J; Nielsen C; Sudre CH; Wilson A; Thai NJ; Blair PS; Coulthard E; Lane JA; Passmore P; Taylor J; Mutsaerts HJ; Thomas DL; Fox NC; Wilkinson I; Ben-Shlomo Y;
    Lancet Neurol; 2021 Nov; 20(11):895-906. PubMed ID: 34687634
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.